Rifampicin and bioavailability in combination formulation;Rifampicina y biodisponibilidad en productos combinados

Ars Pharmaceutica

Volumn 46, Issue 4, 2005, Pages 353-364

  Sosa, M ^a   Szeliga M E ^a   Fernandez A ^a   Bregni, C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Bioavailability; FDC products; Isoniazid; Polymorphism; Rifampicin; Stability

Indexed keywords

AMINOPHYLLINE; AMINOSALICYLIC ACID; AMOBARBITAL; CHLORAMPHENICOL; DIAZEPAM; DIGOXIN; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KETOCONAZOLE; NIFEDIPINE; PHENYLBUTAZONE; PHENYTOIN; PROPRANOLOL; PYRAZINAMIDE; RIFAMPICIN; SILDENAFIL; VERAPAMIL; WARFARIN;

ARTICLE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG STABILITY; HUMAN; PRIMARY HEALTH CARE; SOLID; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 32044470277     PISSN: 00042927     EISSN: 00042927     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. World Health Organization. Report on infectious diseases. Removing obstacles to healthy development. World Health Organization Document 1999;WHO/CDC/99.1:1-68.
2. Goodman y Gilman; Las Bases Farmacológicas de la Terapéutica, Novena edición, 1996, Mc Graw-Hill. Interamericana, México; cap.48: 1225
3. Singh S., Mariappan T.T., Snakar R., Sarda N., Sing B., A Critical review of the probable reasons for the poor/variable bioavailability of rifampicina from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem; Int. J. Pharm 2001, 228: 5-17
4. Gallo G.G, Radaelli P, 1976 Rifampicin In: Florey K (Ed.), Analytical Profiles of Drug Substances, Academic Press, London, pp: 468-513
5. Connors K.A., Amidon G.L.; Stella V.J., Chemical Stability of Pharmaeuticals. Second Edition, p: 728-732
6. Sing S., Mariappan T.T., Sharda N., Kumar S., Chakraborti A.K., The Reason for an Increase in Decomposition of Rifampicin in the Presence of Isoniazid under Acid Conditions, Pharm. Pharmacol. Commun. 2000, 6: 405-410
7. Sing S., Mariappan T.T., Sharda N., Singh B., Degradation of Rifampicin, Isoniazid and Pyrazinamide from Prepared Mixtures and Marketed Single and Combination Products Under Acid Conditions, Pharm. Pharmacol. Commun. 2000, 6: 491-494.
8. Shishoo C. J., Shan S.A., Rathod I.S., Savale S.S., Vora M.J.; Impared Bioavailability of rifampicina in presence of isoniazida from fixed dose combination (FDC) formulation. Int. J. Pharm 2001, 228: 53-67
9. Pelizza G., Nebuloni M., Ferrari P., Gallo G.G, Polymorphism of Rifampicin; Il Fármaco 1977, 32:471-481
10. Henwoood S.Q., Liebenberg W., Tiedt L.R., Lötter A.P, Villiers M.M; Characterization of the Solubility and Dissolution Properties of Several New Rifampicin Polymorphs, Solvates and Hydrates; Drug Dev. Ind. Pharm. 2001, 27(10):1017-30
11. Agrawal S., Ashokraj Y., Bharatam P.V., Pillai O., Panchangnula R.; Solid-state characterization of rifampicina samples and its biopharmaceutic relevance; European J. Pharm. Sci 2004, 22: 127-144
12. Goodman y Gilman; Las Bases Farmacológicas de la Terapéutica, Novena edición, 1996, Mc Graw-Hill. Interamericana, México; cap.48: 1230
13. M. H.Beers, M.D. y R. Berkow, M.D. El Manual Merk. Décima edición, 1999, Harcourt, España, cap.304: 2615.
14. L.R.Lépori P.R. Vademécum Décima edición, 2003, E.C.S.A. Buenos Aires, Sección III Índice de interacciones medicamentosas: 401.
15. Khalil S.A.H., El-Khordagui L.K., El-Gholmy Z.A., Effect of antacids on oral absorption of rifampicina; Int. J. Pharm. 1984, 20:99-106
16. Mariappan T.T., Singh S., Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat; Int. J. Tuberc. Lung Dis. 2003, 7(8):797-803.